EHS
EHS

Triplet Therapeutics, biotech focused on Huntington’s, quietly shuts down



A biotech company co-founded by venture capital firm Atlas Venture has shut down after running into problems with its lead drug and raising new funding.

Triplet Therapeutics, which was based in Cambridge, Mass., launched in 2019 with a $59 million Series A round from a group of VCs including Atlas, MPM Capital, and Pfizer Ventures.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED





Source link

EHS
Back to top button